Literature DB >> 1755152

Prostatic tissue levels of ofloxacin.

J Aagaard1, J Knes, P O Madsen.   

Abstract

The prostatic tissue levels of ofloxacin were determined in 20 patients undergoing transurethral resection of the prostate. Ofloxacin was administered in two separate dosages of 300 mg PO from twenty-two to two hours preoperatively. The ofloxacin plasma concentrations ranged from 3.73 to 1.85 micrograms/mL at the time of surgery, and the tissue concentrations ranged from 4.55 to 1.94 micrograms/mL. The ofloxacin tissue/plasma ratios ranged from 0.9 to 1.2. These findings indicate that ofloxacin may be useful in prophylaxis prior to transurethral prostatic surgery and also in the treatment of bacterial prostatitis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1755152     DOI: 10.1016/0090-4295(91)80159-5

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  4 in total

1.  The 6-fluoro-8-methoxy quinolone gatifloxacin down-regulates interleukin-8 production in prostate cell line PC-3.

Authors:  Koh Takeyama; Hiroaki Mitsuzawa; Chiaki Nishitani; Takeyuki Shimizu; Hitomi Sano; Yasuharu Kunishima; Satoshi Takahashi; Hiroshi Hotta; Masanori Matsukawa; Ken-Ichiro Shibata; Taiji Tsukamoto; Yoshio Kuroki
Journal:  Antimicrob Agents Chemother       Date:  2006-10-16       Impact factor: 5.191

Review 2.  Diagnostic and therapeutic problems in prostatitis. Therapeutic position of ofloxacin.

Authors:  J Aagaard; P O Madsen
Journal:  Drugs Aging       Date:  1992 May-Jun       Impact factor: 3.923

Review 3.  Quinolones as a Potential Drug in Genitourinary Cancer Treatment-A Literature Review.

Authors:  Tomasz Kloskowski; Sylwia Frąckowiak; Jan Adamowicz; Kamil Szeliski; Marta Rasmus; Tomasz Drewa; Marta Pokrywczyńska
Journal:  Front Oncol       Date:  2022-06-08       Impact factor: 5.738

Review 4.  Ofloxacin. A reappraisal of its use in the management of genitourinary tract infections.

Authors:  S V Onrust; H M Lamb; J A Balfour
Journal:  Drugs       Date:  1998-11       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.